Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Both medications are self-administered once weekly via a small injection pen
FDA-Noted Concerns: Increased heart rate Systemic vasodilatory reactions Limited clinical safety data Immunogenicity risk (antibody formation) Reported Side Effects: Injection site reactions (redness, swelling, itching) Headache Flushing Dizziness Nausea Water retention Serious Concerns: Potential for glucose metabolism disruption Theoretical cancer risk (GH/IGF-1 promote cell proliferation) Long-term safety unknown Regulatory Status United States: CJC-1295 is not FDA approved for any indication
Tesamorelin is a prescription-only medication in the United States
Nanomed: Nanotechnol Biol Med (2017) 13:65965
The clinical dosage range spans 2.510 mg per subcutaneous injection, titrated over 4 weeks before reaching a maintenance dose of 510 mg, five times weekly
US$ 26.59
US$ 24.45
US$ 25.82
